ESMO 2022 | Current standards and future prospects for the treatment of hormone refractory prostate cancer
Fred Saad, MD, FRCS, University of Montreal Hospital Center, Montreal, Canada, provides an overview of the standard of care for metastatic castration resistant prostate cancer (mCRPC), including chemotherapy and novel hormones such as abiraterone and enzalutamide. Olaparib has also been approved for patients who have progressed on first-line novel hormonal agents, and the addition of Lutecium PSMA has shown improvements to overall-survival (OS). Prof. Saad emphasizes the importance of identifying high-risk patients to be treated as early as possible.This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Right now we have several drugs that improve survival in metastatic castration-resistant disease. That includes chemotherapy, it includes novel hormonals like abiraterone and enzalutamide. But what we’ve added to that list now is olaparib, for patients who have progressed on first line novel hormonal agents; and most recently, just recently approved, is Pluvicto, or lutetium PSMA, which also showed improvements in overall survival...
Right now we have several drugs that improve survival in metastatic castration-resistant disease. That includes chemotherapy, it includes novel hormonals like abiraterone and enzalutamide. But what we’ve added to that list now is olaparib, for patients who have progressed on first line novel hormonal agents; and most recently, just recently approved, is Pluvicto, or lutetium PSMA, which also showed improvements in overall survival.
The thing to remember is that all of these drugs were actually compared to either a placebo or a non-life prolonging control arm. So the bar is very high now to continue to show that we can do even better when we’re comparing to one of the standard-of-care therapies. So it’s very exciting that we have a lot to offer for mCRPC, but what’s most important is we’re realizing that when we take these drugs that are effective and bring them earlier in the hormone-sensitive setting or trying to delay metastases, we do even better. And so really, the future is really trying to identify high risk patients and treat them as early as possible.
Read more...
